title: Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.
abstract: OBJECTIVE
  IGF-I (insulin growth factor 1) is crucially involved in cellular proliferation. Moreover, deregulation of IGF-I has been shown to be relevant in the carcinogenesis of various tumor entities. However, the impact of IGF-I in epithelial ovarian cancer (EOC) is unclear. In the present study, we investigated the predictive and prognostic role of circulatory IGF-I in primary EOC patients.
  
  
  METHODS
  In the FP6 European Project "OVCAD", 275 consecutive primary EOC patients were enrolled. Patients were eligible if radical cytoreductive surgery and platinum-based chemotherapy were performed. Plasma IGF-I was detected using ELISA.
  
  
  RESULTS
  Increased plasma IGF-I levels were more frequently found in well-differentiated epithelial ovarian carcinoma (p=0.0047). A weak correlation was observed between IGF-I levels and CA-125 in patients with serous EOC (p=0.04). No association between IGF-I expression and other clinico-pathological parameters was observed.
  
  
  CONCLUSIONS
  IGF-I is overexpressed in patients with well-differentiated EOC. Further studies are warranted to elucidate the role of IGF-I in this sub-group of patients.
authors.affiliation: Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Irena
authors.initials: I
authors.lastname: Rohr
authors.affiliation: Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Cluster Translational Oncology, General Hospital of Vienna, Vienna, Austria.
authors.forename: Robert
authors.initials: R
authors.lastname: Zeillinger
authors.affiliation: Alice Salomon University of Applied Sciences, Berlin, Germany and Center for Chronic Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Michaela
authors.initials: M
authors.lastname: Heinrich
authors.affiliation: Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Nicole
authors.initials: N
authors.lastname: Concin
authors.affiliation: Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.affiliation: Ovarian Cancer Tumor Bank (TOC), Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Mani
authors.initials: M
authors.lastname: Nassir
authors.affiliation: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Mahner
authors.affiliation: Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.
authors.forename: Els
authors.initials: E
authors.lastname: VAN Nieuwenhuysen
authors.affiliation: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Fabian
authors.initials: F
authors.lastname: Trillsch
authors.affiliation: Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Cluster Translational Oncology, General Hospital of Vienna, Vienna, Austria.
authors.forename: Dan
authors.initials: D
authors.lastname: Cacsire-Tong
authors.affiliation: Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Radoslav
authors.initials: R
authors.lastname: Chekerov
authors.affiliation: Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany jalid.sehouli@charite.de.
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.affiliation: Gynecological Tumor Center and European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany Ovarian Cancer Tumor Bank (TOC), Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Elena I
authors.initials: EI
authors.lastname: Braicu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000378:metabolism; D000077216:Carcinoma, Ovarian Epithelial; D065426:Cytoreduction Surgical Procedures; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D018394:CA-125 Antigen; C583557:IGF1 protein, human; C451759:MUC16 protein, human; D008565:Membrane Proteins; D009944:Organoplatinum Compounds; D007334:Insulin-Like Growth Factor I
keywords: IGF1; low-grade serous carcinoma; ovarian cancer